#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave of KRAS pro­grams

The first time I sat down with Am­gen’s Greg Friberg to talk about the phar­ma gi­ant’s KRAS G12C pro­gram for so­tora­sib (AMG 510) at AS­CO a lit­tle more than a year ago, there was high ex­cite­ment about the first glimpse of ef­fi­ca­cy from their Phase I study, with 5 of 10 evalu­able non-small cell lung can­cer pa­tients demon­strat­ing a re­sponse to the drug.

Af­ter decades of fail­ure tar­get­ing KRAS, so­tora­sib of­fered the first pos­i­tive look at a new ap­proach that promised to open a door to a whole new ap­proach by tar­get­ing a par­tic­u­lar mu­ta­tion to a big tar­get that had re­mained “un­drug­gable” for decades.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER